SlideShare a Scribd company logo
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Published Chemotherapy Regimens Schedule 1 Cisplaitn 50 mg/m 2  days 1 and 8 Vinorelbine 25 mg/m 2  days 1, 8, 15, 22 Every 28 days for 4 cycles 2 Cisplaitn 100 mg/m 2  on day 1  Vinorelbine 30 mg/m 2  days 1, 8, 15, 22 Every 28 days for 4 cycles 3 Cisplaitn 75-80 mg/m 2  on day 1 Vinorelbine 25-30 mg/m 2  days 1, 8 Every 28 days for 4 cycles 4 Cisplaitn 100 mg/m 2  on day 1 Etoposide 100 mg/m 2  day 1-3 Every 28 days for 4 cycles 5 Cisplaitn 80 mg/m 2  day 1 Vinblastine 4 mg/m 2  days 1, 8, 15, 22 Every 28 days for 4 cycles Acceptable Cisplaitn-base Regimens 1 Cisplatin 80 mg/m 2  on day 1 Gemcitabine 1000 mg/m 2  on days 1, 8 Every 21 days 2 Cisplatin 80 mg/m 2 Docetaxel 75 mg/m 2 Every 21 days Chemotherapy Regimens for patients with comorbidities or patients not able to tolerate cisplatin 1 Paclitaxel 200 mg/m 2  on day 1 Carboplatin AUC 6 on day 1 Every 21 days
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],Regimens Patients % 1 Gemcetabine + Cisplatin  29 30.53 2 Gemcetabine + Carboplatin  8 8.42 3 Gemcetabine + Platinum base + Radiotherapy 14 14.74 4 Gemcetabine + Platinum base + Avastin 4 4.21 5 Etoposite + Platinum base 15 15.79 6 Etoposite + Platinum base + Radiotherapy 2 2.10 7 Taxane base + Platinum base 14 14.74 8 Taxane base + Platinum base + Radiotherapy 6 6.31 9 Taxane base + Platinum base + Avastin 3 3.16
[object Object],Regimens  patients 1 Docetaxel 75-80 mg/ m 2   7 2 Irinotecan 200 mg/ m 2   3 3 Tarceva 150 mg/ m 2   5 4 Iressa 250 mg/ m 2   5
 
 
 
[object Object]
Regimes  GC GCar GPR GPA Total No. 29 8 14 4 No. % No. % No. % No. % Anaemia 4 13.79 1 12.50 4 28.57 - - Leucopenia 16 55.17 5 62.50 9 64.28 3 75 Lymphopenia 3 10.34 1 12.50 2 14.29 2 50 Thrombopenia 6 20.69 3 37.50 5 35.71 - - N & V 12 41.38 2 25.00 9 64.28 2 50 Increase Cr 4 13.79 1 12.50 3 21.43 - - Diarrhoea 2 6.90 - - 2 14.29 - - Hepatotoxicity 1 3.45 2 25.00 - - - - Fever 4 13.79 2 25.00 3 21.43 - - Nephrotoxicity 1 3.45 - - - - - - Fatigue  10 34.48 4 50.00 8 57.14 - -
 
Regimes  EP TP TPR Total No. 15 14 6 No. % No. % No. % Anaemia - - - - 1 16.67 Leucopenia - - 6 42.86 3 50 Thrombopenia - - - - 1 16.67 N & V 4 26.67 3 21.43 2 33.33 Diarrhoea - - - - 1 16.67 Fever 1 6.67 1 7.14 1 16.67 Nephrotoxicity 1 6.67 - - - - Neuropathy - - 3 21.43 - - Fatigue  - - 3 21.43 1 16.67 Myalgia - - 3 21.43 - -
 
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
 

More Related Content

What's hot

Melanoma frontline approach
Melanoma frontline approachMelanoma frontline approach
Melanoma frontline approach
Ereny Samwel
 
Multimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii NsclcMultimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii Nsclc
fondas vakalis
 
Molecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Molecular Therapeutics with Chemotherapy in SCCHN by J. VermorkenMolecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Molecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Eurasian Federation of Oncology
 
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapyMCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
European School of Oncology
 
8 jason westin
8 jason westin8 jason westin
8 jason westin
spa718
 

What's hot (20)

Melanoma frontline approach
Melanoma frontline approachMelanoma frontline approach
Melanoma frontline approach
 
Olaparib in Metastatic Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer Olaparib in Metastatic Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer
 
Multimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii NsclcMultimodality Treatment Of Stage Iii Nsclc
Multimodality Treatment Of Stage Iii Nsclc
 
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...
Concurrent Chemoradiation in Postoperative Setting In LAHNC. A comparision of...
 
RefractoryCRPC management
RefractoryCRPC managementRefractoryCRPC management
RefractoryCRPC management
 
Cco melanoma
Cco melanomaCco melanoma
Cco melanoma
 
Allogeneic Stem Cell Transplant for Hodgkin's Lymphoma
Allogeneic Stem Cell Transplant for Hodgkin's LymphomaAllogeneic Stem Cell Transplant for Hodgkin's Lymphoma
Allogeneic Stem Cell Transplant for Hodgkin's Lymphoma
 
Metronomic chemotherapy in mbc
Metronomic chemotherapy in mbcMetronomic chemotherapy in mbc
Metronomic chemotherapy in mbc
 
1- mutahir tunio
 1- mutahir tunio 1- mutahir tunio
1- mutahir tunio
 
Metronomic Chemotherapy
Metronomic ChemotherapyMetronomic Chemotherapy
Metronomic Chemotherapy
 
Cancer gastrico adyuvancia
Cancer gastrico adyuvanciaCancer gastrico adyuvancia
Cancer gastrico adyuvancia
 
Molecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Molecular Therapeutics with Chemotherapy in SCCHN by J. VermorkenMolecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
Molecular Therapeutics with Chemotherapy in SCCHN by J. Vermorken
 
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapyMCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
MCO 2011 - Slide 17 - J.B. Vermorken - Systemic therapy
 
ImmunoOncology in Lung Cancer
ImmunoOncology in Lung CancerImmunoOncology in Lung Cancer
ImmunoOncology in Lung Cancer
 
Targeted Therapy for Melanoma - Dr. Michael Davies
Targeted Therapy for Melanoma - Dr. Michael DaviesTargeted Therapy for Melanoma - Dr. Michael Davies
Targeted Therapy for Melanoma - Dr. Michael Davies
 
Cetuximab in scchn how far we go?
Cetuximab in scchn  how far we go?Cetuximab in scchn  how far we go?
Cetuximab in scchn how far we go?
 
Systemic Therapy for Metastatic Disease
Systemic Therapy for Metastatic DiseaseSystemic Therapy for Metastatic Disease
Systemic Therapy for Metastatic Disease
 
Developing a Test to Predict Side Effects of Chemotherapy in Patients with Co...
Developing a Test to Predict Side Effects of Chemotherapy in Patients with Co...Developing a Test to Predict Side Effects of Chemotherapy in Patients with Co...
Developing a Test to Predict Side Effects of Chemotherapy in Patients with Co...
 
8 jason westin
8 jason westin8 jason westin
8 jason westin
 
Peripheral Blood Stem Cell Transplant
Peripheral Blood Stem Cell TransplantPeripheral Blood Stem Cell Transplant
Peripheral Blood Stem Cell Transplant
 

Viewers also liked

Dosage Calculation Using Formula Method
Dosage Calculation Using Formula MethodDosage Calculation Using Formula Method
Dosage Calculation Using Formula Method
windleh
 
B A S I C S O F Pharmacology
B A S I C S  O F  PharmacologyB A S I C S  O F  Pharmacology
B A S I C S O F Pharmacology
Bob Bin
 
Colorectal surgery and stomas
Colorectal surgery and stomasColorectal surgery and stomas
Colorectal surgery and stomas
meducationdotnet
 
18 basics of pediatric airway anatomy, physiology and management
18 basics of pediatric airway anatomy, physiology and management18 basics of pediatric airway anatomy, physiology and management
18 basics of pediatric airway anatomy, physiology and management
Dang Thanh Tuan
 

Viewers also liked (14)

Dosage Calculation Using Formula Method
Dosage Calculation Using Formula MethodDosage Calculation Using Formula Method
Dosage Calculation Using Formula Method
 
Dosage Regimen
Dosage RegimenDosage Regimen
Dosage Regimen
 
B A S I C S O F Pharmacology
B A S I C S  O F  PharmacologyB A S I C S  O F  Pharmacology
B A S I C S O F Pharmacology
 
Colorectal surgery and stomas
Colorectal surgery and stomasColorectal surgery and stomas
Colorectal surgery and stomas
 
Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt. Mdr tb & xdr tb ppt.
Mdr tb & xdr tb ppt.
 
Drug Calculation
Drug CalculationDrug Calculation
Drug Calculation
 
Mdr tuberculosis
Mdr tuberculosisMdr tuberculosis
Mdr tuberculosis
 
Pediatric Medication
Pediatric MedicationPediatric Medication
Pediatric Medication
 
18 basics of pediatric airway anatomy, physiology and management
18 basics of pediatric airway anatomy, physiology and management18 basics of pediatric airway anatomy, physiology and management
18 basics of pediatric airway anatomy, physiology and management
 
INTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGYINTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGY
 
An Introduction to Pharmacology
An Introduction to PharmacologyAn Introduction to Pharmacology
An Introduction to Pharmacology
 
Colorectal Cancer
Colorectal CancerColorectal Cancer
Colorectal Cancer
 
Introduction to basic principles of pharmacology
Introduction to basic principles of pharmacologyIntroduction to basic principles of pharmacology
Introduction to basic principles of pharmacology
 
Pediatric drug dose calculation
Pediatric drug dose calculationPediatric drug dose calculation
Pediatric drug dose calculation
 

Similar to Aung thiha soe

Phase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomidePhase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomide
seayat1103
 
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...
European School of Oncology
 
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer  BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
European School of Oncology
 
Temozolomide and thalidomide for treatment of neuroendocrine tumor
Temozolomide and thalidomide for treatment of neuroendocrine tumorTemozolomide and thalidomide for treatment of neuroendocrine tumor
Temozolomide and thalidomide for treatment of neuroendocrine tumor
seayat1103
 
Targeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s LymphomaTargeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s Lymphoma
spa718
 
Targeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s LymphomaTargeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s Lymphoma
spa718
 
Pancreatic Cancer Are We Moving Forward Yet
Pancreatic Cancer Are We Moving Forward YetPancreatic Cancer Are We Moving Forward Yet
Pancreatic Cancer Are We Moving Forward Yet
fondas vakalis
 

Similar to Aung thiha soe (20)

brenutuximab-journal club.pptx
brenutuximab-journal club.pptxbrenutuximab-journal club.pptx
brenutuximab-journal club.pptx
 
Phase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomidePhase ii study of temozolomide and thalidomide
Phase ii study of temozolomide and thalidomide
 
Portec 3
Portec 3Portec 3
Portec 3
 
( )Anal scc
( )Anal scc( )Anal scc
( )Anal scc
 
Erbitux
ErbituxErbitux
Erbitux
 
IO en NSCLC
IO en NSCLCIO en NSCLC
IO en NSCLC
 
Clinical Development of ADC Drugs Targeting TROP-2.pdf
Clinical Development of ADC Drugs Targeting TROP-2.pdfClinical Development of ADC Drugs Targeting TROP-2.pdf
Clinical Development of ADC Drugs Targeting TROP-2.pdf
 
Journal club on Ca Anal Canal
Journal club on Ca Anal CanalJournal club on Ca Anal Canal
Journal club on Ca Anal Canal
 
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MD
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MDTargeted Therapy for Uveal Melanoma - Richard Carvajal, MD
Targeted Therapy for Uveal Melanoma - Richard Carvajal, MD
 
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...
Medical Students 2011 - J.B. Vermorken - GYNAECOLOGICAL CANCER SESSION - Epit...
 
Success story of m tor inhibitors in m rcc
Success story of m tor inhibitors in m rccSuccess story of m tor inhibitors in m rcc
Success story of m tor inhibitors in m rcc
 
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer  BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
 
STUPP TRIAL - treatment of high grade glioma
STUPP TRIAL - treatment of high grade gliomaSTUPP TRIAL - treatment of high grade glioma
STUPP TRIAL - treatment of high grade glioma
 
Temozolomide and thalidomide for treatment of neuroendocrine tumor
Temozolomide and thalidomide for treatment of neuroendocrine tumorTemozolomide and thalidomide for treatment of neuroendocrine tumor
Temozolomide and thalidomide for treatment of neuroendocrine tumor
 
Chemotherapy in gliomas
Chemotherapy in gliomas Chemotherapy in gliomas
Chemotherapy in gliomas
 
Targeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s LymphomaTargeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s Lymphoma
 
Targeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s LymphomaTargeted therapy for Hodgkin’s Lymphoma
Targeted therapy for Hodgkin’s Lymphoma
 
070125 chemotherapy for hn scc2
070125 chemotherapy for hn scc2070125 chemotherapy for hn scc2
070125 chemotherapy for hn scc2
 
Side Effects Management for the Ovarian Cancer Community
Side Effects Management for the Ovarian Cancer CommunitySide Effects Management for the Ovarian Cancer Community
Side Effects Management for the Ovarian Cancer Community
 
Pancreatic Cancer Are We Moving Forward Yet
Pancreatic Cancer Are We Moving Forward YetPancreatic Cancer Are We Moving Forward Yet
Pancreatic Cancer Are We Moving Forward Yet
 

More from zawhtet1984

Tanl power point
Tanl power pointTanl power point
Tanl power point
zawhtet1984
 
Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)
zawhtet1984
 
Powerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihaPowerpoint presentation by dr sathiha
Powerpoint presentation by dr sathiha
zawhtet1984
 
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Aung myo zaw(nutrition in  preterm and congenital hypotrophy)Aung myo zaw(nutrition in  preterm and congenital hypotrophy)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
zawhtet1984
 

More from zawhtet1984 (11)

Yehlaingbwar
YehlaingbwarYehlaingbwar
Yehlaingbwar
 
Tanl power point
Tanl power pointTanl power point
Tanl power point
 
Kyaw thura zaw
Kyaw thura zawKyaw thura zaw
Kyaw thura zaw
 
Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)Pyae phyo aung's thesis (breast cancer)
Pyae phyo aung's thesis (breast cancer)
 
Zaw htet
Zaw htetZaw htet
Zaw htet
 
Sithu ko
Sithu koSithu ko
Sithu ko
 
Powerpoint presentation by dr sathiha
Powerpoint presentation by dr sathihaPowerpoint presentation by dr sathiha
Powerpoint presentation by dr sathiha
 
Khant zaw aung
Khant zaw aungKhant zaw aung
Khant zaw aung
 
Chan myae htut
Chan myae htutChan myae htut
Chan myae htut
 
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
Aung myo zaw(nutrition in  preterm and congenital hypotrophy)Aung myo zaw(nutrition in  preterm and congenital hypotrophy)
Aung myo zaw(nutrition in preterm and congenital hypotrophy)
 
Aung citt nyein
Aung citt nyeinAung citt nyein
Aung citt nyein
 

Recently uploaded

The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
kaushalkr1407
 
plant breeding methods in asexually or clonally propagated crops
plant breeding methods in asexually or clonally propagated cropsplant breeding methods in asexually or clonally propagated crops
plant breeding methods in asexually or clonally propagated crops
parmarsneha2
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
CarlosHernanMontoyab2
 

Recently uploaded (20)

The geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideasThe geography of Taylor Swift - some ideas
The geography of Taylor Swift - some ideas
 
Benefits and Challenges of Using Open Educational Resources
Benefits and Challenges of Using Open Educational ResourcesBenefits and Challenges of Using Open Educational Resources
Benefits and Challenges of Using Open Educational Resources
 
Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345Sha'Carri Richardson Presentation 202345
Sha'Carri Richardson Presentation 202345
 
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
GIÁO ÁN DẠY THÊM (KẾ HOẠCH BÀI BUỔI 2) - TIẾNG ANH 8 GLOBAL SUCCESS (2 CỘT) N...
 
How to Create Map Views in the Odoo 17 ERP
How to Create Map Views in the Odoo 17 ERPHow to Create Map Views in the Odoo 17 ERP
How to Create Map Views in the Odoo 17 ERP
 
The Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdfThe Roman Empire A Historical Colossus.pdf
The Roman Empire A Historical Colossus.pdf
 
Home assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdfHome assignment II on Spectroscopy 2024 Answers.pdf
Home assignment II on Spectroscopy 2024 Answers.pdf
 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa
 
Basic phrases for greeting and assisting costumers
Basic phrases for greeting and assisting costumersBasic phrases for greeting and assisting costumers
Basic phrases for greeting and assisting costumers
 
Instructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptxInstructions for Submissions thorugh G- Classroom.pptx
Instructions for Submissions thorugh G- Classroom.pptx
 
plant breeding methods in asexually or clonally propagated crops
plant breeding methods in asexually or clonally propagated cropsplant breeding methods in asexually or clonally propagated crops
plant breeding methods in asexually or clonally propagated crops
 
Matatag-Curriculum and the 21st Century Skills Presentation.pptx
Matatag-Curriculum and the 21st Century Skills Presentation.pptxMatatag-Curriculum and the 21st Century Skills Presentation.pptx
Matatag-Curriculum and the 21st Century Skills Presentation.pptx
 
1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx1.4 modern child centered education - mahatma gandhi-2.pptx
1.4 modern child centered education - mahatma gandhi-2.pptx
 
50 ĐỀ LUYỆN THI IOE LỚP 9 - NĂM HỌC 2022-2023 (CÓ LINK HÌNH, FILE AUDIO VÀ ĐÁ...
50 ĐỀ LUYỆN THI IOE LỚP 9 - NĂM HỌC 2022-2023 (CÓ LINK HÌNH, FILE AUDIO VÀ ĐÁ...50 ĐỀ LUYỆN THI IOE LỚP 9 - NĂM HỌC 2022-2023 (CÓ LINK HÌNH, FILE AUDIO VÀ ĐÁ...
50 ĐỀ LUYỆN THI IOE LỚP 9 - NĂM HỌC 2022-2023 (CÓ LINK HÌNH, FILE AUDIO VÀ ĐÁ...
 
678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf678020731-Sumas-y-Restas-Para-Colorear.pdf
678020731-Sumas-y-Restas-Para-Colorear.pdf
 
INU_CAPSTONEDESIGN_비밀번호486_업로드용 발표자료.pdf
INU_CAPSTONEDESIGN_비밀번호486_업로드용 발표자료.pdfINU_CAPSTONEDESIGN_비밀번호486_업로드용 발표자료.pdf
INU_CAPSTONEDESIGN_비밀번호486_업로드용 발표자료.pdf
 
Chapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptxChapter 3 - Islamic Banking Products and Services.pptx
Chapter 3 - Islamic Banking Products and Services.pptx
 
Synthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptxSynthetic Fiber Construction in lab .pptx
Synthetic Fiber Construction in lab .pptx
 
Salient features of Environment protection Act 1986.pptx
Salient features of Environment protection Act 1986.pptxSalient features of Environment protection Act 1986.pptx
Salient features of Environment protection Act 1986.pptx
 
How to Break the cycle of negative Thoughts
How to Break the cycle of negative ThoughtsHow to Break the cycle of negative Thoughts
How to Break the cycle of negative Thoughts
 

Aung thiha soe

  • 1.
  • 2.
  • 3.
  • 4. Published Chemotherapy Regimens Schedule 1 Cisplaitn 50 mg/m 2 days 1 and 8 Vinorelbine 25 mg/m 2 days 1, 8, 15, 22 Every 28 days for 4 cycles 2 Cisplaitn 100 mg/m 2 on day 1 Vinorelbine 30 mg/m 2 days 1, 8, 15, 22 Every 28 days for 4 cycles 3 Cisplaitn 75-80 mg/m 2 on day 1 Vinorelbine 25-30 mg/m 2 days 1, 8 Every 28 days for 4 cycles 4 Cisplaitn 100 mg/m 2 on day 1 Etoposide 100 mg/m 2 day 1-3 Every 28 days for 4 cycles 5 Cisplaitn 80 mg/m 2 day 1 Vinblastine 4 mg/m 2 days 1, 8, 15, 22 Every 28 days for 4 cycles Acceptable Cisplaitn-base Regimens 1 Cisplatin 80 mg/m 2 on day 1 Gemcitabine 1000 mg/m 2 on days 1, 8 Every 21 days 2 Cisplatin 80 mg/m 2 Docetaxel 75 mg/m 2 Every 21 days Chemotherapy Regimens for patients with comorbidities or patients not able to tolerate cisplatin 1 Paclitaxel 200 mg/m 2 on day 1 Carboplatin AUC 6 on day 1 Every 21 days
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.  
  • 12.  
  • 13.  
  • 14.
  • 15. Regimes GC GCar GPR GPA Total No. 29 8 14 4 No. % No. % No. % No. % Anaemia 4 13.79 1 12.50 4 28.57 - - Leucopenia 16 55.17 5 62.50 9 64.28 3 75 Lymphopenia 3 10.34 1 12.50 2 14.29 2 50 Thrombopenia 6 20.69 3 37.50 5 35.71 - - N & V 12 41.38 2 25.00 9 64.28 2 50 Increase Cr 4 13.79 1 12.50 3 21.43 - - Diarrhoea 2 6.90 - - 2 14.29 - - Hepatotoxicity 1 3.45 2 25.00 - - - - Fever 4 13.79 2 25.00 3 21.43 - - Nephrotoxicity 1 3.45 - - - - - - Fatigue 10 34.48 4 50.00 8 57.14 - -
  • 16.  
  • 17. Regimes EP TP TPR Total No. 15 14 6 No. % No. % No. % Anaemia - - - - 1 16.67 Leucopenia - - 6 42.86 3 50 Thrombopenia - - - - 1 16.67 N & V 4 26.67 3 21.43 2 33.33 Diarrhoea - - - - 1 16.67 Fever 1 6.67 1 7.14 1 16.67 Nephrotoxicity 1 6.67 - - - - Neuropathy - - 3 21.43 - - Fatigue - - 3 21.43 1 16.67 Myalgia - - 3 21.43 - -
  • 18.  
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.